Table 1 Clinical characteristics of the study sample (Melbourne Collaborative Cohort Study, N = 425 women)
From: Tumour DNA methylation markers associated with breast cancer survival: a replication study
Clinical characteristics | N women (%) | All-cause death (%) | Breast cancer death (%) | |
|---|---|---|---|---|
| Â | 425 (100) | 168 (40) | 66 (16) | |
IHC-based subtype | Luminal A | 242 (57) | 101 (42) | 33 (14) |
Luminal B | 87 (20) | 32 (37) | 12 (14) | |
HER2-positive | 31 (7) | 10 (32) | 7 (23) | |
Triple-negative | 65 (15) | 25 (38) | 14 (22) | |
Stage | I | 246 (58) | 79 (32) | 14 (6) |
II | 135 (32) | 57 (42) | 28 (21) | |
III/IV | 44 (10) | 32 (73) | 24 (55) | |
Country of birth | Aust/NZ/Other | 344 (81) | 136 (40) | 52 (15) |
Northern Europe | 20 (5) | 9 (45) | 5 (25) | |
Southern Europe | 61 (14) | 23 (38) | 9 (15) | |
Age, median (IQR)1 |  | 64 (57–70) |  |  |
Tumour purity, median (IQR) |  | 0.63 (0.55–0.70) |  |  |